Beta-blockers Prevent Sudden Death: so Why Is Their Use Limited after Myocardial Infarction?

  • M. Lunati
  • M. Gasparini
  • G. Magenta
  • G. Cattafi
  • G. Gadaleta


There is overwhelming evidence that in the post myocardial infarction (MI) setting β-blockers (BB) are of benefit (in terms of safety and efficacy): they reduce recurrent MI, sudden death (SD) mortality, total mortality especially in patients with depressed ventricular function [1–14].


Acute Myocardial Infarction Antiarrhythmic Drug Antiarrhythmic Agent Necrotic Myocardium Ventricular Effective Refractory Period 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Norwegian Multicentre Study Group (1981) Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 309: 801–807Google Scholar
  2. 2.
    Beta-blockers Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 247: 1707–1714CrossRefGoogle Scholar
  3. 3.
    Herlitz J, Wilhelmsen C, Holmberg S et al (1984) The Goteborg Metoprolol Trial in Acute Myocardial Infarction. Am J Cardiol 53 (suppl D): 1D–50DGoogle Scholar
  4. 4.
    The Miami Trial Research Group (1985) Metoprolol in Acute Myocardial Infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 6: 199–226Google Scholar
  5. 5.
    Yusuf S, Peto R, Lewis J et al (1985) Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Progr Cardiovasc Dis 27: 335–371CrossRefGoogle Scholar
  6. 6.
    The Beta-blockers Pooling Project Research Group (1988) The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in postinfarction patients. Eur Heart J 9: 8–16CrossRefGoogle Scholar
  7. 7.
    Boissel JP, Leizorovicz A, Picolet H et al (1990) Secondary prevention after high risk acute myocardial infarction with low dose acebutolol. Am J Cardiol 66: 251–260PubMedCrossRefGoogle Scholar
  8. 8.
    Olson G (1992) Metoprolol induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 13: 28–32Google Scholar
  9. 9.
    Pitt B (1992) The role of ß-adrenergic blocking agents in preventing sudden cardiac death. Circulation 85 (suppl I): 1107–1115Google Scholar
  10. 10.
    Yusuf S, Lessem J, Jha P et al (1993) Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 11 (suppl 4): S61–S63Google Scholar
  11. 11.
    Held P (1993) Effects of betablockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects. Am J Cardiol 71 (9): 39C–44CPubMedCrossRefGoogle Scholar
  12. 12.
    Viscoli CM, Horwitz RI, Singer BH (1993) Beta-blockers after myocardial infarction: influence of first year clinical course on long term effectiveness. Ann Intern Med 118: 99–105PubMedCrossRefGoogle Scholar
  13. 13.
    Teo KK, Yusuf S, Furberg CD (1993) Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 270: 1589–1595PubMedCrossRefGoogle Scholar
  14. 14.
    Castaigne A, Carville AF, Chazouilleres AF et al (1995) Le traitement médical après l’infarctus du myocarde: ordonnance réflexe ou ordonnance réfléchie. Arch Mal Coeur 88 (III): 45–49PubMedGoogle Scholar
  15. 15.
    Reiffel J, Estes NAM III, Waldo AL et al (1994) A consensus report on antiarrhythmic drug use. Clin Cardiol 17: 103–110PubMedCrossRefGoogle Scholar
  16. 16.
    Ryan TJ, Anderson JL, Antman EM et al (1996) ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. Circulation 94: 2341–2350PubMedCrossRefGoogle Scholar
  17. 17.
    Cairns JA, Connolly SJ (1995) The problem of asymptomatic ventricular arrhythmias among survivors of acute myocardial infarction: role of amiodarone. ACC Current J Review 4 (2): 32–34CrossRefGoogle Scholar
  18. 18.
    Kennedy HL, Brooks MM, Barker AH et al (1994) Beta-Blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 74: 674–680PubMedCrossRefGoogle Scholar
  19. 19.
    Kjekshus J, Gilpin E, Cali G et al (1990) Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 10: 423–428Google Scholar
  20. 20.
    Forman DE, Gutierrez Bernal JL, Wey JY (1992) Management of acute myocardial infarction in the very elderly. Am J Med 93: 315–326PubMedCrossRefGoogle Scholar
  21. 21.
    Yusuf S, Wittes J, Probstifield J (1990) Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q wave myocardial infarction and beta-blockers. Am J Cardiol 66: 220–222PubMedCrossRefGoogle Scholar
  22. 22.
    Glamann DB, Lange RA, Hillis LD (1991) Beneficial effects of long term beta-blockade after acute myocardial infarction in patients without anterograde flow in the infarct artery. Am J Cardiol 68: 150–154PubMedCrossRefGoogle Scholar
  23. 23.
    Singh BN (1996) New antiarrhythmic drugs for ventricular arrhythmias: do they work? In: Raviele A (ed) Cardiac arrhythmias 1995. Springer, Berlin Heidelberg New York, pp 31–38Google Scholar
  24. 24.
    Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving flecainide, encainide and placebo: the Cardiac Arrhytmia Suppression Trial. N Engl J Med 324: 781–788PubMedCrossRefGoogle Scholar
  25. 25.
    Schwartz PJ (1996) What have we learned from the SWORD trial? Can potassium channel blockers reduce sudden cardiac death? In: Raviele A (ed) Cardiac arrhythmias 1995. Springer, Berlin Heidelberg New York, pp 39–42Google Scholar
  26. 26.
    Avanzini F, Latini R, Maggioni A et al (1995) Antiarrhythmic drug prescription in patients after myocardial infarction in the last decade. Arch Intern Med 155: 1041–1045PubMedCrossRefGoogle Scholar
  27. 27.
    Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273: 1450–1456PubMedCrossRefGoogle Scholar
  28. 28.
    Ferguson D (1966) Meeting highlights. Circulation 94: 3–6Google Scholar
  29. 29.
    Naccarella FF, Palmieri M, Barbato G et al (1997) Critical evaluation of controlled clinical trials of antiarrhythmic therapy in the prevention of sudden death. In: Santini M (ed) Progress in clinical pacing 1996. Futura Media Services, New York, pp 531–546Google Scholar
  30. 30.
    Maggioni A (1997) personal communicationGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • M. Lunati
    • 1
  • M. Gasparini
    • 1
  • G. Magenta
    • 1
  • G. Cattafi
    • 1
  • G. Gadaleta
    • 1
  1. 1.Servizio di Elettrofisiologia ed Elettrostimolazione, Dipartimento Cardiologico “A. De Gasperis”Ospedale Ca’ GrandaMilano-NiguardaItaly

Personalised recommendations